Table 3 Clinical trials cancers for treatment of patients with PTEN-deficient. Tables and data are adopted from clinicaltrials.gov. (https://clinicaltrials.gov/)
Status of trial | Conditions | Interventions of clinical trial | Study type | Study completion time |
|---|---|---|---|---|
Recruiting | • PTEN mutation and PTEN hamartoma Tumor Syndrome (PHTS) | • Drug: RAD001 and placebo | Interventional, phases 1 and 2 | 2019 |
Recruiting | • Advanced solid tumors with PTEN or PIK3CB mutations • Anatomic stage III BC AJCC v8 and anatomic stage IIIA BC AJCC | • Drug: Docetaxel, PI3Kbeta and AZD8186 inhibitor • Biomarker evaluation | Interventional, phase 1 | 2021 |
Completed | • Cowden’s disease • PHTS | • Fludeoxyglucose F 18 as radiotherapy • Drug: Sirolimus | Interventional, phase 2 | 2012 |
Recruiting | • Cancer and solid tumors with AKT1, 2, 3 genetic changes, activating PI3K mutations, PTEN mutations | • Drug: ARQ 751 | Interventional, phase 1 | 2019 |
Active, not recruiting | • Advanced cancers with PI3KCA mutation, Positive/PTEN under-expression | • Drug: Pazopanib and Everolimus | Interventional, phase 1 | – |
Not yet recruiting | • Metastatic BC with AR+ and PTEN+ | • Drug: Alpelisib (BYL719), and Enzalutamide (androgen receptor inhibitor) | Interventional, phase 1 | 2021 |
Completed | • Evaluation of tumor suppressor gene PTEN endometrial neoplasms | • Behavioral: questionnaire • DNA testing/tumor-genetic markers | Observational study | 2011 |
Terminated | • c-MET inhibitor; PI3K inhibitor, PTEN mutations, homozygous del. PTEN neg. | • Drug: INC280 and Buparlisib | Interventional, phases 1 and 2 | 23, 2016 |
Recruiting | • Metastatic melanoma and PTEN loss, malignancy of skin • Metastatic melanoma | • Drug: GSK2636771 and Pembrolizumab | Interventional, phases 1 and 2 | 2021 |
Recruiting | • Carcinoma, squamous cell of head and neck with PI3KCA mutation and/or PTEN under-expression | • Drug: Copanlisib and Cetuximab | Interventional, phases 1 and 2 | 2020 |
Completed | • Advanced solid tumors with PTEN deficiency | • Drug: GSK2636771 | Interventional, phase 2 | 2016 |
Recruiting | • Advanced cancers with somatic mutation in BRCA1/2 • Mutations/or deletions in PTEN /or PTEN under-expression | • Drug: Talazoparib Tosylate | Interventional, phase 2 | 2020 |
Recruiting | • BC with PIK3CA/AKT1/PTEN-alteration • TNBC | • Drug: Ipatasertib, paclitaxel and placebo | Interventional, phases 1 and 2 | 2021 |